Technical Analysis for CGTX - Cognition Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.60% | |
| NR7 | Range Contraction | 0.60% | |
| Narrow Range Bar | Range Contraction | 0.60% | |
| Inside Day | Range Contraction | 0.60% | |
| Wide Bands | Range Expansion | 0.60% | |
| Down 3 Days in a Row | Weakness | 0.60% | |
| Down 4 Days in a Row | Weakness | 0.60% | |
| Down 5 Days in a Row | Weakness | 0.60% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Up 5% | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/08/2024
Cognition Therapeutics, Inc. Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Biology Alzheimer's Disease Parkinson's Disease Disorders Dementia Psychiatric Diagnosis Geriatrics Aging Associated Diseases Lewy Body Dementia Cognitive Disorders Dry Age Related Macular Degeneration Early Stage Alzheimer's Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.95 |
| 52 Week Low | 0.9001 |
| Average Volume | 141,792 |
| 200-Day Moving Average | 1.76 |
| 50-Day Moving Average | 2.00 |
| 20-Day Moving Average | 1.94 |
| 10-Day Moving Average | 1.85 |
| Average True Range | 0.15 |
| RSI (14) | 36.71 |
| ADX | 20.97 |
| +DI | 20.75 |
| -DI | 26.17 |
| Chandelier Exit (Long, 3 ATRs) | 1.99 |
| Chandelier Exit (Short, 3 ATRs) | 2.07 |
| Upper Bollinger Bands | 2.33 |
| Lower Bollinger Band | 1.55 |
| Percent B (%b) | 0.15 |
| BandWidth | 40.01 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.048 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.83 | ||||
| Resistance 3 (R3) | 1.85 | 1.80 | 1.81 | ||
| Resistance 2 (R2) | 1.80 | 1.76 | 1.80 | 1.80 | |
| Resistance 1 (R1) | 1.74 | 1.74 | 1.71 | 1.72 | 1.79 |
| Pivot Point | 1.69 | 1.69 | 1.68 | 1.69 | 1.69 |
| Support 1 (S1) | 1.63 | 1.65 | 1.61 | 1.62 | 1.55 |
| Support 2 (S2) | 1.58 | 1.63 | 1.58 | 1.54 | |
| Support 3 (S3) | 1.52 | 1.58 | 1.53 | ||
| Support 4 (S4) | 1.51 |
